• 2Q FY25 operating revenue down 38.6% to $30.8 million
• US down 43.7% to $25.3 million, ANZ up 1.9% to $5.4 million
• 2Q FY25 gross profit margin improvement up 8.4 ppts to 63.6%

MedAdvisor Limited (ASX: MDR) reports its financial results for the quarter ended 31 December 2024 (2Q FY25). 2Q FY25 operating revenue was down 38.6% to $30.8 million, with the US down 43.7% to $25.3 million primarily due to deferrals in vaccine-related health programs from two key pharma clients, while the ANZ region was up 1.9% to $5.4 million. Gross profit margin improved by 8.4 ppts to 63.6%. The company has commenced a previously planned business restructure, expected to result in annual cost savings of at least $5.0 million in FY26. Cash on hand was $12.4 million as at 31 December 2024. The company has also initiated a formal review to evaluate strategic options to maximise shareholder value, which is progressing well. The company expects a stronger second half through a diversified US pipeline for various health programs, as well as a number of new customer accounts currently being finalised. Positive first half EBITDA guidance is confirmed.

The company expects a stronger second half through a diversified US pipeline for various health programs, as well as a number of new customer accounts currently being finalised. Positive first half EBITDA guidance is confirmed.

The company remains confident that it is well positioned and executing on strategic initiatives geared towards developing the foundations for a sustainable profitable growth business.